PolyPid (NASDAQ:PYPD – Get Free Report) and NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Profitability
This table compares PolyPid and NewAmsterdam Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PolyPid | N/A | -241.96% | -126.91% |
| NewAmsterdam Pharma | -943.23% | -26.49% | -24.37% |
Earnings & Valuation
This table compares PolyPid and NewAmsterdam Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PolyPid | N/A | N/A | -$34.17 million | ($1.91) | -2.72 |
| NewAmsterdam Pharma | $22.50 million | 161.32 | -$203.82 million | ($1.79) | -17.35 |
PolyPid has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations for PolyPid and NewAmsterdam Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PolyPid | 1 | 0 | 4 | 0 | 2.60 |
| NewAmsterdam Pharma | 1 | 1 | 9 | 1 | 2.83 |
PolyPid currently has a consensus price target of $11.67, suggesting a potential upside of 124.79%. NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 57.81%. Given PolyPid’s higher possible upside, equities research analysts plainly believe PolyPid is more favorable than NewAmsterdam Pharma.
Institutional and Insider Ownership
26.5% of PolyPid shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 24.7% of PolyPid shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Risk and Volatility
PolyPid has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.
Summary
NewAmsterdam Pharma beats PolyPid on 8 of the 14 factors compared between the two stocks.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
About NewAmsterdam Pharma
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
